Weight loss drug is not taking easy way out

Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
Oprah Winfrey faces backlash for making bold claim about ‘thin people’ after taking weight-loss drug
"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.
Oprah Winfrey opens up on weight loss, understanding thinness
Oprah Winfrey admitted two years ago to taking diabetes medication to lose weight. In a new podcast episode, she revealed that this process helped her understand "thin" people. Oprah Winfrey has struggled with weight issues for years.
Oprah Winfrey Admits Weight Loss Journey Changed Her Perception of 'Thin People'
Oprah Winfrey shared on her podcast how Ozempic changed her views on "thin people," realizing food noise isn't just willpower.
Oprah Winfrey criticised for her latest theory on 'thin people'
The TV queen is being criticised on social media after revealing her new theory on appetite, in light of her experience using a weight-loss drug to shed pounds. "One of the things that I realised the very first time I took a GLP-1 was that all these years I thought that thin people - those people - just had more willpower,
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Diabetes startup Virta Health is now prescribing Ozempic for weight loss in a push toward profitability and IPO
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
I work 3 jobs to pay for my semaglutide weight loss shots — now I’m locked-in for life
“I’m making money to afford semagultide,” Rice, 42, who works three jobs to afford the expensive injectables, explained to her over 14,000 TikTok fans . Classified as a GLP-1, appetite-suppressing ...
6 Common Side Effects from Taking a GLP-1 Medication—and How to Manage Them
If your constipation lasts for more than 3 days, speak with your doctor about options to help. You might need to add a stool ...
Demand for loose skin surgery rises with GLP-1 weight loss meds
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...
Neuroscience News2d
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...